Immunoglobulin Or Antibody Binds An Expression Product Of A Cancer Related Gene Or Fragment Thereof (e.g., Oncogene, Proto-oncogene, Etc.) Patents (Class 435/330)
-
Publication number: 20090081241Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS:1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.Type: ApplicationFiled: November 14, 2008Publication date: March 26, 2009Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
-
Patent number: 7498306Abstract: The invention relates to novel synthetic or natural E4orf4 or Bcl-2 peptides particularly useful in antitumoral, antiviral and antiparasitic treatments, said peptides being less than 30 amino acids long and binding in vitro to a phosphatase 2A protein holoenzyme or one of its subunits. The invention also relates to polynucleotides encoding the novel peptides, vectors expressing same, as well as antibodies identifying same and probes identifying transcripts thereof.Type: GrantFiled: April 18, 2005Date of Patent: March 3, 2009Assignee: Institut PasteurInventors: Alphonse Garcia, Frederic Dessauge, Xavier Cayla, Angelita Rebollo
-
Publication number: 20090010841Abstract: This invention provides novel prostate cancer specific internalizing human antibodies. The antibodies are useful by themselves to prevent growth and/or proliferation of prostate cancer cells. The antibodies can also be formulated as chimeric molecules to direct an effector (e.g. a cytotoxin, an imaging reagent, a drug, etc.) to a prostate tumor site.Type: ApplicationFiled: January 10, 2008Publication date: January 8, 2009Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Bin Liu, James D. Marks
-
Publication number: 20080267872Abstract: A novel gene 098P4B6 (also designated STEAP-2) and its encoded protein, and variants thereof, are described wherein 98P4B6 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 98P4B6 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 98P4B6 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 98P4B6 can be used in active or passive immunization.Type: ApplicationFiled: September 22, 2006Publication date: October 30, 2008Inventors: Arthur B. Raitano, Wangmag Ge, Aya Jakobovits, Pia M. Challita-Eid, Mary Faris
-
Publication number: 20080254026Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.Type: ApplicationFiled: October 31, 2007Publication date: October 16, 2008Applicant: Novartis Vaccines and Diagnostics, Inc.Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Bao-Lu Chen, Xiaofeng Lu, Sang Hoon Lee, Deborah Hurst, Sharon Lea Aukerman, Daniel E. Lopes de Menezes
-
Patent number: 7435590Abstract: The present invention establishes a simple and a highly sensitive detection method for hEPR and provides a novel detection method for human tumors which express hEPR. In particular, the present invention provides a monoclonal antibody which specifically recognizes human epiregulin (hEPR), hybridoma which produces the monoclonal antibody, and a highly sensitive detection method for hEPR using the monoclonal antibody.Type: GrantFiled: March 15, 2004Date of Patent: October 14, 2008Assignee: Taisho Pharmaceutical Co., Ltd.Inventor: Toshi Komurasaki
-
Publication number: 20080247944Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to IRTA-2 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting IRTA-2, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma.Type: ApplicationFiled: January 12, 2006Publication date: October 9, 2008Inventors: Robert Graziano, David J. King, Mohan Srinivasan, Josephine M. Cardarelli, Haichun Huang
-
Publication number: 20080241137Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.Type: ApplicationFiled: March 25, 2008Publication date: October 2, 2008Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto
-
Publication number: 20080233122Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.Type: ApplicationFiled: October 31, 2007Publication date: September 25, 2008Applicants: Abgenix, Inc., Pfizer Inc.Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
-
Publication number: 20080226635Abstract: An antibody binding to IGF-IR and being glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is between 20% and 50%, has improved properties in antitumor therapy.Type: ApplicationFiled: December 11, 2007Publication date: September 18, 2008Inventors: Hans Koll, Klaus-Peter Kuenkele, Samuel Moser, Sylke Poehling
-
Publication number: 20080219972Abstract: A nucleic acid molecule comprising at least one nucleotide sequence encoding SEQ ID NO: 14, 15, 19, 41, or a sequence that is at least about 95% identical thereto; a composition comprising same and a method of administering same to induce an immune response; a polypeptide consisting of SEQ ID NO: 14, 15, 19, 41, or a sequence that is at least about 95% identical thereto; a composition comprising same and a method of administering same to induce an immune response; a composition comprising APC, which have been exposed to the polypeptide, and a method of administering same to treat prostate cancer; a composition comprising T-cells, which are specific for an epitope in a polypeptide consisting of SEQ ID NO: 14, 15, 19, or 41 and a method of administering same to treat prostate cancer; a composition comprising an anti-idiotypic antibody having an internal image of an epitope of a polypeptide consisting of SEQ ID NO: 14, 15, 19, or 41 and a method of administering same to treat prostate cancer; and an immortal B-cType: ApplicationFiled: August 16, 2006Publication date: September 11, 2008Applicant: UNIVERSITY OF MARYLAND, BALTIMOREInventors: Elena N. Klyushnenkova, Richard B. Alexander
-
Patent number: 7413899Abstract: The present invention relates to cDNA sequences from a region of amplification on chromosome 20 associated with disease. The sequences can be used in hybridization methods for the identification of chromosomal abnormalities associated with various diseases. The sequences can also be used for treatment of diseases.Type: GrantFiled: February 6, 2006Date of Patent: August 19, 2008Assignees: The Hospital for Sick Children, The Regents of the University of CaliforniaInventors: Joe W Gray, Colin Conrad Collins, Soo-in Hwang, Tony Godfrey, David Kowbel, Johanna Rommens
-
Publication number: 20080187532Abstract: An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody.Type: ApplicationFiled: September 28, 2007Publication date: August 7, 2008Inventors: Austin Gurney, Fumiko Axelrod, Tim Hoey, Sanjeev Satyal
-
Patent number: 7405061Abstract: Provided herein is disclosure about the identification and characterization of disease and cancer associated antigen PIPA. The invention also provides a family of monoclonal antibodies that bind to antigen PIPA, and methods of diagnosing and treating various human cancers and diseases that express PIPA.Type: GrantFiled: November 13, 2003Date of Patent: July 29, 2008Assignee: Raven biotechnologies, inc.Inventors: Jennie P. Mather, Ronghao Li, Tony W. Liang
-
Publication number: 20080178308Abstract: A novel prostate tumor associated gene (designated 24P4C12) and its encoded protein is described. 24P4C12 is highly expressed in prostate tissue xenografts, providing evidence that it is turned on in at least some prostate cancers. 24P4C12 provides a diagnostic and/or therapeutic target for prostate and other cancers.Type: ApplicationFiled: August 20, 2007Publication date: July 24, 2008Applicant: AGENSYS, INC.Inventors: Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran
-
Publication number: 20080171043Abstract: The present invention provides novel antibodies specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells, but do not specifically bind to a CD43 expressed by a leukocyte or by a Jurkat cell, and is capable of inducing apoptosis of the nonhematopoietic cancer cell after binding to the epitope on cell surface of the nonhematopoietic cancer cell in the absence of cytotoxin conjugation and immune effector function, wherein the epitope comprises a carbohydrate structure and the binding of the antibody to the epitope is inhibited by a carbohydrate comprising a Lea structure, a Lea-lactose structure, a LNDFH II structure, or a LNT structure. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.Type: ApplicationFiled: June 7, 2007Publication date: July 17, 2008Inventors: Rong-Hwa Lin, Leewen Lin, Shih-Yao Lin, Shu-Hua Lee
-
Publication number: 20080131433Abstract: Provided herein are antibodies having the same epitope specificity as an antibody produced by the hybridoma cell line deposited with the American Type Culture Collection as hybridoma 4-2A6, 1-5A3, or 1-3B4. Further provided herein are methods of identifying and selecting cells that express FcRH1 or FcRH4. Methods of diagnosing and treating a subject with a malignancy of a hematopoietic cell lineage or an autoimmune disease and methods of modulating a humoral immune response in a subject are also provided herein. Further provided herein are polypeptides comprising one or more complementary determining regions of the disclosed antibodies and nucleic acids that encode the disclosed polypeptides.Type: ApplicationFiled: September 27, 2005Publication date: June 5, 2008Applicant: THE UAB RESEARCH FOUNDATIONInventors: Randall S. Davis, Max D. Cooper, Chuen-Miin Leu, Goetz R. Ehrhardt
-
Publication number: 20080131434Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.Type: ApplicationFiled: May 31, 2007Publication date: June 5, 2008Inventors: John A. Lewicki, Austin Gurney, Timothy Hoey, Wan-Ching Yen, Sanjeev Satyal
-
Publication number: 20080118935Abstract: Methods and compositions for determining whether a subject at least has a neoplastic disease are provided. In practicing the subject methods, a sample from a subject is assayed for a soluble filamin analyte, such as a filamin A analyte, to determine whether the subject at least has the neoplastic disease. Also provided are kits, systems, and devices for practicing the subject methods.Type: ApplicationFiled: October 9, 2007Publication date: May 22, 2008Applicant: INVITROGEN CORPORATIONInventor: Ozge Alper
-
Patent number: 7374936Abstract: The present invention relates to the field of site directed therapy. More specifically the invention relates to site directed radio therapy, and provides a method for production of radioconjugates and an apparatus for radioimmunotherapy. The method, conjugates and apparatus can be practicalized without the need for radioactive shielding and/or airtight facilities. Without these restrictions the invention provides a simple and efficient means of therapy at the bed-side of the patient.Type: GrantFiled: December 17, 2001Date of Patent: May 20, 2008Assignee: Actinium Pharmaceuticals, Inc.Inventor: Maurits W Geerlings
-
Publication number: 20080108133Abstract: A purified polypeptide that binds to neoplastic cells, which may be an antibody, is produced by the hybridoma SAM-6, a method for its production and use in the treatment and diagnosis of neoplasms.Type: ApplicationFiled: November 12, 2004Publication date: May 8, 2008Inventors: Heinz Vollmers, Hans-Konrad Muller-Hermelink
-
Patent number: 7351583Abstract: A novel gene (designated PHOR-1) that is highly over-expressed in prostate and other cancers and its encoded protein are described. PHOR-1 is a G protein-coupled receptor with homology to receptors involved in olfaction. PHOR-1 in normal human tissues is restricted to prostate, and this gene is highly over-expressed in prostate cancer as well as in cancers of the kidney, uterus, cervix, stomach and rectum. Consequently, PHOR-1 provides a diagnostic and/or therapeutic target for prostate cancer.Type: GrantFiled: November 16, 2004Date of Patent: April 1, 2008Assignee: Agensys, Inc.Inventors: Arthur B. Raitano, Daniel E. H. Afar, Aya Jakobovits, Mary Faris, Rene S. Hubert, Steven Chappell Mitchell, Douglas Saffran
-
Patent number: 7335747Abstract: Myc protein is an unevenly distributed intermediate agent for cell proliferation, and activates a gene expression via E.box. Mina53 gene encodes a protein of 53 kDa molecular weight and is present in the nucleoplasm and nucleolus. Mina53 mRNA and protein expression are induced by artificial introduction of c-Myc activity. E.box site is present in the vicinity of the transcription initiation site of mina53 gene, and the expression from mina53 promoter is activated by c-Myc through the medium of E.box. Specific inhibition of mina53 expression in HeLa cells and rat fibroblast cells 3Y1 having high expression c.myc strikingly inhibits cell proliferation. The combination of these results show that mina53 is a Myc target gene and is associated with cell proliferation in mammals.Type: GrantFiled: April 14, 2003Date of Patent: February 26, 2008Assignee: Gakkouhoujin Kurume UniversityInventors: Makoto Tsuneoka, Hiroshi Kimura
-
Patent number: 7319139Abstract: Methods, compositions and kits comprising dimeric antibodies for the treatment of neoplastic, autoimmune or other disorders are provided. The dimeric antibodies of the instant invention may comprise two antibody molecules (H4L4) having the same antigen binding specificity (homodimers) or, alternatively, may comprise two different antibody molecules having binding specificity for two distinct antigens (heterodimers). In preferred embodiments the antibody molecules comprising the dimers are non-covalently associated.Type: GrantFiled: January 29, 2002Date of Patent: January 15, 2008Assignee: Biogen Idec, Inc.Inventors: Gary R Braslawsky, Nabil Hanna, Paul Chinn, Kandasamy Hariharan
-
Patent number: 7276372Abstract: GPR64 antibody compositions are provided. These antibodies may be used for diagnosis or treatment of cancer, especially ovarian cancer, Ewing's sarcoma, uterine cancer, and other GPR64 expressing tumor types.Type: GrantFiled: December 19, 2003Date of Patent: October 2, 2007Assignee: PDL Biopharma, Inc.Inventors: Debbie Law, Qi Wang, Robert DuBridge, Vinay Bhaskar
-
Patent number: 7253263Abstract: The present invention relates to a human CDR-grafted antibody against ganlioside GD3 (hereinafter referred to “GD3”), derivatives of an anti-GD3 antibody and cytokine, and use for treatment and diagnosis of the antibody and the derivatives.Type: GrantFiled: September 29, 2000Date of Patent: August 7, 2007Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Nobuo Hanai, Kenya Shitara, Kazuyasu Nakamura, Rinpel Niwa
-
Patent number: 7226750Abstract: The present invention is directed to cell surface antigenes found on myeloma cells and on ovarian cancer cells that are recognized by monoclonal antibodies, and antibody binding fragments thereof, as described. The monoclonal antibodies of the invention are capable of being used for therapeutic, screening, diagnostic and cell purification purposes. A representative and exemplified monoclonal antibody of the present invention recognizes and binds to an epitope common to a surface antigen that is expressed on multiple myeloma cells and to a surface antigen that is expressed on ovarian cancer cells. The function of this monoclonal antibody both in vivo and in vitro is demonstrated.Type: GrantFiled: August 8, 2000Date of Patent: June 5, 2007Assignee: Molecular Discoveries, Inc.Inventor: Cohava Gelber
-
Patent number: 7223549Abstract: The invention provides monoclonal antibodies that selectively bind to ectodermally- and endodermally-derived stem cells and methods for the diagnosis of a neoplasm in a subject by contacting a tissue sample from the subject with the antibodies. Also disclosed are methods for isolating such stem cells from a heterogeneous cell population by contacting the population with antibodies which selectively bind to stem cells.Type: GrantFiled: December 10, 2002Date of Patent: May 29, 2007Inventor: Andrew N. Makarovskiy
-
Patent number: 7148038Abstract: Provided herein is disclosure about the development and characterization of an antibody (mPA7) which binds to antigen CD46 which is present on a variety of human cancers from ovary, breast, lung, prostate, colon, kidney, and pancreas. Methods of diagnosing and treating various cancers by using antibodies such as mPA7 directed against this antigen are also disclosed.Type: GrantFiled: October 16, 2002Date of Patent: December 12, 2006Assignee: Raven biotechnologies, inc.Inventor: Jennie P. Mather
-
Patent number: 7118912Abstract: The disclosure provides, among other things, molecular markers for categorizing the neoplastic state of a patient, methods for using the molecular markers in diagnostic tests, nucleic acid and amino acid sequences related to the molecular markers, reagents for detection of molecular markers, and methods for identifying candidate molecular markers in highly parallel gene expression data.Type: GrantFiled: October 18, 2002Date of Patent: October 10, 2006Assignee: Case Western Reserve UniversityInventor: Sanford D. Markowitz
-
Patent number: 7101979Abstract: Antibody to endostatin protein that is an inhibitor of endothelial cell proliferation, capable of inhibiting angiogenesis and causing tumor regression, that is approximately 18 kDa as determined by non-reduced gel electrophoresis, and approximately 20 kDa as determined by reduced gel electrophoresis and corresponds to a C-terminal fragment of collagen type XVIII, and methods of detecting and treating angiogenesis-related disease therewith.Type: GrantFiled: May 9, 2002Date of Patent: September 5, 2006Assignee: The Children's Medical Center CorporationInventors: Thomas Boehm, Michael S. O'Reilly, M. Judah Folkman
-
Patent number: 7074613Abstract: The invention concerns a hybridome called 5C5 (CNCM no I-2184) and the monoclonal antibody 5C5 which it produces. Said monoclonal antibody which specifically recognises most human renal cell carcinomas, is developed for diagnosing, imaging and treating human renal cell carcinomas.Type: GrantFiled: May 10, 2000Date of Patent: July 11, 2006Assignee: Centre National de la Rechershe ScientifiqueInventors: François Hirsch, Eric Angevin
-
Patent number: 7064188Abstract: Hybridomally produced monoclonal antibodies specifically immunoreactive with the glycoprotein carrying the CA 125 epitope. Monoclonal antibodies recognize both high and low molecular weight subunits of the antigen, and identify the antigen in the cytoplasm and the extracellular matrix of CA 125 producing cells. An immunoassay for the detection of CA 125 utilizing the monoclonal antibodies is described.Type: GrantFiled: September 9, 2002Date of Patent: June 20, 2006Assignee: The Board of Trustees of the University of ArkansasInventor: Timothy J. O'Brien
-
Patent number: 7056702Abstract: The invention provides antibodies reactive with distinct lipocalin epitopes that are useful for detecting inflammation and bacterial infections in mammals.Type: GrantFiled: December 16, 2002Date of Patent: June 6, 2006Inventors: Julie M. Villanueva, Stephen Quirk
-
Patent number: 7029866Abstract: The invention is directed to a method of diagnosis of the existence and/or the pathological developmental stage and/or the grade of malignancy of carcinomas and/or sarcomas in mammals characterized by the preparation of a body sample of said mammals and the determination of the overexpression of the protein Nup88 in said sample and to antibodies suitable for performing the same.Type: GrantFiled: October 10, 2000Date of Patent: April 18, 2006Inventors: Hanswalter Zentgraf, Susanne Franz, Angel Alonso, Nerea Martinez
-
Patent number: 6984382Abstract: A bifunctional protein comprising: 1) a single-chain antibody directed against a suitable antigen on a tumour cell, 2) a hinge region comprising from about 40 to about 200 amino acids joined to the VL domain of the single chain antibody, and 3) a functional zeta (?) chain from the T-cell antigen receptor (TCR) joined to the hinge region, wherein the hinge region is an immunoglobin-like hinge region which is joined to the C-terminus of the VL domain of the single-chain antibody. The functional zeta (?) chain comprises the transmembrane and the cytoplasmic domain. The bifunctional protein can be expressed using a cytotoxic lymphocyte (CTL) expressing DNA encoding it.Type: GrantFiled: June 19, 2000Date of Patent: January 10, 2006Inventors: Bernd Groner, Dirk Moritz
-
Patent number: 6955924Abstract: The instant invention provides for the identification, diagnosis, monitoring, and treatment of invasive cells using the laminin 5 gamma-2 chain protein or nucleic acid sequence, or antibodies thereto.Type: GrantFiled: January 8, 2001Date of Patent: October 18, 2005Assignee: BioStratum, Inc.Inventors: Karl Tryggvason, Pekka Kallunki, Charles Pyke
-
Patent number: 6872568Abstract: The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity.Type: GrantFiled: May 4, 2000Date of Patent: March 29, 2005Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Reiner L. Gentz, Guo-Liang Yu, Craig A. Rosen
-
Patent number: 6855508Abstract: The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA method and kits for VEGF as an antigen were developed to detect VEGF levels in biological samples from animal models and human patients and are used as a diagnostic/prognostic index.Type: GrantFiled: August 5, 2002Date of Patent: February 15, 2005Assignee: Genentech, Inc.Inventors: David Tai Wai Fei, Kristen Tomita
-
Patent number: 6843990Abstract: The invention provides monoclonal antibodies against decoy receptor 3 (DcR3), hybridomas producing said antibodies, kits containing said monoclonal antibodies and uses of the hybridomas, antibodies and kits for the detection of DcR3-associated diseases, as well as for the treatment and/or prevention of DcR3-associated diseases.Type: GrantFiled: December 3, 2001Date of Patent: January 18, 2005Assignee: Anawrahta Biotech Co.Inventors: Mai Shen-Chih, Liu Shih-Jen
-
Patent number: 6825324Abstract: The protein tyrosine kinase receptors, designated Rse and HPTK6, have been purified from human and/or murine cell tissues. Rse and HPTK6 have been cloned from a cDNA library of a human liver carcinoma cell line (i.e., Hep 3B) using PCR amplification. Provided herein are nucleic acid sequences encoding Rse and HPTK6 useful as diagnostics and in the recombinant preparation of Rse and HPTK6. Rse and HPTK6 are used in the preparation and purification of antibodies thereto and in diagnostic assays.Type: GrantFiled: December 30, 1998Date of Patent: November 30, 2004Assignee: Genentech, Inc.Inventors: Kevin P. Baker, Will F. Baron
-
Patent number: 6693176Abstract: Antibodies that bind to a 40 kDa protein which is expressed on tumors, but is not expressed on normal adult hemopoietic cells are disclosed. Also disclosed are methods for production and the use of such antibodies.Type: GrantFiled: July 18, 2000Date of Patent: February 17, 2004Assignee: University of MassachusettsInventors: Kenneth L. Rock, Dancella Fernandes
-
Patent number: 6689607Abstract: The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding human TR11, TR11SV1, and TR11SV2 receptors. TR11, TR11SV1, and TR11SV2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR11, TR11SV1, and TR11SV2 receptor activity. The present invention further relates to antibodies that specifically bind TR11, TR11SV1, and/or TR11SV2. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR11, TR11SV1, and TR11SV2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR11, TR11SV1, and TR11SV2 receptors.Type: GrantFiled: July 27, 2001Date of Patent: February 10, 2004Assignee: Human Genome Sciences, Inc.Inventors: Jian Ni, Steven M. Ruben
-
Patent number: 6670466Abstract: The present invention is related to mammary tumor virus (MTV). MTV represents a group of retroviruses which possess very high homology to mouse mammary tumor virus (MMTV), a virus known to cause neoplastic mammary disease in mice. As described herein, MTV's have been identified in human, cat, and Rhesus macaque. The present invention specifically provides for recombinant nucleic acids and polypeptides derived from these MTV's as well as methods for using these biological molecules.Type: GrantFiled: December 19, 2001Date of Patent: December 30, 2003Assignee: The Administrators of the Tulane Educational FundInventor: Robert F. Garry
-
Patent number: 6632620Abstract: The invention provides monoclonal antibodies that selectively bind to ectodermally- and endodermally-derived stem cells and methods for the diagnosis of a neoplasm in a subject by contacting a tissue sample from the subject with the antibodies. Also disclosed are methods for isolating such stem cells from a heterogeneous cell population by contacting the population with antibodies which selectively bind to stem cells.Type: GrantFiled: June 22, 2000Date of Patent: October 14, 2003Inventor: Andrew N. Makarovskiy
-
Patent number: 6617434Abstract: The present invention provides Methyl- (or Mutant-) Differential Display (MDD) methods and nucleic acid probes for detecting mutations and the methylation patterns of nucleic acids. Regions of the genome are differentially methylated or mutated in different cell types, including cancerous cell types. The TSP50 gene is thereby identified and found to be differentially expressed in breast cancer cells. The present invention provides methods and compositions for identifying aberrant expression of the TSP50 gene and of tsp50 protein. Antibodies of the present invention can be used for diagnosis and treatment of diseases characterized by aberrant tsp50 expression.Type: GrantFiled: June 30, 1999Date of Patent: September 9, 2003Assignee: North Shore Long Island Jewish Research InstituteInventor: Hao-Peng Xu Duffy
-
Patent number: 6613538Abstract: The present invention relates to the detection of HLA-G. Antibodies to both soluble and membrane bound HLA-G are disclosed. Exemplary antibodies include 2C/C8, 3C/G4, and 4H84. 2C/C8 and 4H84 antibodies bind to the same region of HLA-G, which is a different region than that bound by 3C/G4. Methods of detection and diagnosis are disclosed as well as kits, including a miniaturized assay suitable for a clinical setting. Further, a method of selecting an embryos for in vitro fertilization is disclosed. A sandwich ELISA test is provided using two antibodies that bind to HLA-G at different regions. The HLA-G test according to the invention is over 1000 times more selective in binding to HLA-G than to antigens HLA-A2, HLA-B4, HLA-C, or mixed WBC preparations.Type: GrantFiled: March 21, 2001Date of Patent: September 2, 2003Inventors: Clifford L. Librach, Shang-mian Yie
-
Patent number: 6573096Abstract: The invention provides antibodies to a membrane protease complex, consisting of two homodimers of seprase and dipeptidyl peptidase IV (DPPIV), obtained from human cell membranes. The antibodies specifically bind the DPPIV protease of the seprase-DPPIV complex that resides on cell surface invadopodia at the leading edge of angiogenic endothelia, migratory fibroblasts, and invading cancer cells, while failing to react with resting cells in adjacent human tissues and blood vessels. These antibodies block interaction of collagen matrix with the seprase-DPPIV complex in the invasive cells during angiogenesis and cancer spreading but not that with other endothelia or tumor cells. The invention further provides methods of using DPPIV antagonists to inhibit capillary sprouting, angiogenesis and cancer invasion in tumor tissues and metastases. Also provided are therapeutic compositions comprising DPPIV antagonists.Type: GrantFiled: April 3, 2000Date of Patent: June 3, 2003Assignee: The Research Foundation at State University of New YorkInventor: Wen-Tien Chen
-
Patent number: 6475775Abstract: The invention describes nucleic acids encoding the PARG protein, including fragments and biologically functional variants thereof. Also included are polypeptides and fragments thereof encoded by such nucleic acids, and antibodies relating thereto. Methods and products for using such nucleic acids and polypeptides also are provided.Type: GrantFiled: May 8, 2000Date of Patent: November 5, 2002Assignee: Ludwig Institute for Cancer ResearchInventors: Jan Saras, Petra Franzén, Pontus Aspenström, Ulf Hellman, Leonel Jorge Gonez, Carl-Henrik Heldin
-
Patent number: RE39760Abstract: Monoclonal antibodies, in particular 33.28 and 31.1, and chimeric antibodies, in particular mouse/humans chimeric Chi #1 specific for glycoprotein antigens of colon carcinoma-associated antigens which are immunogenic in humans, are disclosed. Such antibodies, and fragments and derivatives thereof, are useful in immunodiagnosis and immunotherapy of human colon, breast, and ovarian cancer, and for purification of antigens which can serve as immunotherapeutic agents. Methods of detecting the colon carcinoma-associated antigen in a sample, and methods for treating subjects having colon, breast, and ovarian carcinomas are disclosed.Type: GrantFiled: August 4, 2000Date of Patent: August 7, 2007Assignee: International Bio-Immune Systems Inc.Inventors: Kwong Y. Tsang, Myron Arlen